Cadence Capital Management LLC boosted its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 74.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 109,074 shares of the biopharmaceutical company’s stock after purchasing an additional 46,468 shares during the quarter. Cadence Capital Management LLC owned about 0.24% of Vanda Pharmaceuticals worth $1,658,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Dynamic Technology Lab Private Ltd raised its holdings in shares of Vanda Pharmaceuticals by 46.3% during the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 20,510 shares of the biopharmaceutical company’s stock worth $335,000 after buying an additional 6,487 shares in the last quarter. University of Notre Dame DU Lac bought a new stake in shares of Vanda Pharmaceuticals in the 3rd quarter valued at about $2,824,000. Vanguard Group Inc. grew its position in shares of Vanda Pharmaceuticals by 7.5% in the 2nd quarter. Vanguard Group Inc. now owns 2,680,895 shares of the biopharmaceutical company’s stock valued at $43,698,000 after buying an additional 186,548 shares during the last quarter. Rothschild Asset Management Inc. bought a new stake in shares of Vanda Pharmaceuticals in the 3rd quarter valued at about $23,491,000. Finally, Northern Trust Corp grew its position in shares of Vanda Pharmaceuticals by 16.5% in the 2nd quarter. Northern Trust Corp now owns 597,928 shares of the biopharmaceutical company’s stock valued at $9,747,000 after buying an additional 84,834 shares during the last quarter. Institutional investors and hedge funds own 88.19% of the company’s stock.
VNDA has been the topic of several research analyst reports. Oppenheimer restated a “buy” rating and set a $25.00 target price on shares of Vanda Pharmaceuticals in a research report on Sunday, November 12th. Zacks Investment Research raised Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $18.00 price target on the stock in a research note on Tuesday, October 24th. Jefferies Group reaffirmed a “buy” rating and set a $20.00 price target on shares of Vanda Pharmaceuticals in a research note on Tuesday, February 13th. Seaport Global Securities initiated coverage on Vanda Pharmaceuticals in a research note on Friday, January 19th. They issued a “buy” rating and a $20.00 price objective for the company. Finally, BidaskClub raised Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, December 22nd. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company. Vanda Pharmaceuticals currently has an average rating of “Buy” and an average target price of $21.43.
Shares of Vanda Pharmaceuticals Inc. (NASDAQ VNDA) traded up $0.20 during midday trading on Friday, reaching $17.10. The company’s stock had a trading volume of 442,553 shares, compared to its average volume of 557,612. Vanda Pharmaceuticals Inc. has a 1-year low of $11.90 and a 1-year high of $18.99.
Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.12) by $0.08. Vanda Pharmaceuticals had a negative return on equity of 11.97% and a negative net margin of 9.43%. The firm had revenue of $44.28 million during the quarter, compared to analyst estimates of $44.00 million. During the same period last year, the company earned $0.08 earnings per share. The business’s revenue for the quarter was up 15.8% on a year-over-year basis. equities research analysts predict that Vanda Pharmaceuticals Inc. will post -0.33 EPS for the current year.
In other Vanda Pharmaceuticals news, insider Mihael Hristos Polymeropoulos sold 191,760 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $15.30, for a total transaction of $2,933,928.00. Following the sale, the insider now owns 1,031,848 shares in the company, valued at $15,787,274.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Gunther Birznieks sold 8,568 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $15.26, for a total value of $130,747.68. Following the sale, the senior vice president now owns 118,366 shares in the company, valued at approximately $1,806,265.16. The disclosure for this sale can be found here. Insiders sold 209,483 shares of company stock worth $3,205,205 in the last quarter. 7.60% of the stock is currently owned by company insiders.
WARNING: “Cadence Capital Management LLC Has $1.66 Million Stake in Vanda Pharmaceuticals Inc. (VNDA)” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/18/vanda-pharmaceuticals-inc-vnda-position-increased-by-cadence-capital-management-llc.html.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.